Description: Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
Home Page: www.newron.com
Via Antonio Meucci 3
Bresso,
MI
20091
Italy
Phone:
39 02 610 3461
Officers
| Name | Title |
|---|---|
| Mr. Stefan Weber | CEO & Exec. Director |
| Mr. Roberto Galli | VP of Fin. |
| Mr. Marco Caremi | Exec. VP of Bus. Devel. |
| Dr. Ravi Anand | Chief Medical Officer |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 14.2248 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.9786 |
| Price-to-Sales TTM: | 3.9482 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 25 |